Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e74277852f1aae0a3ff13f59a65456d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-11001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2018-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f75b5038c20e97f075a1a5b88cfe8aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6196283d04bdcc5f1cf09280477f8aa4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d1c5f0932a561182685f52f21b8b6e9 |
publicationDate |
2021-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3785768-A1 |
titleOfInvention |
Target for drug treatment of tumor metastasis and use thereof |
abstract |
Disclosed is a use of PRAK as a drug target in screening a drug for inhibiting or preventing tumor cell metastasis. Based on the discovery that PRAK can be used as a target for tumor cell metastasis, further provided is a drug capable of inhibiting or preventing tumor cell metastasis. The active ingredient of the drug can reduce the expression level of PRAK or inhibit the bioactivity of PRAK, and the inhibition or prevention of tumor cell metastasis can be achieved by regulating the cell migration and the expression and/or function of HIF1α, MMP2 and/or EMT series molecules. |
priorityDate |
2018-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |